These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 6113729)
21. Tardive dyskinesia in schizophrenics under 60 years of age. Kolakowska T; Williams AO; Ardern M; Reveley MA Biol Psychiatry; 1986 Feb; 21(2):161-9. PubMed ID: 2868762 [TBL] [Abstract][Full Text] [Related]
22. [Current status of neuroleptic long term treatment of schizophrenia]. Woggon B; Angst J; Margoses N Nervenarzt; 1975 Nov; 46(11):611-6. PubMed ID: 813157 [No Abstract] [Full Text] [Related]
23. Tolerability of low dose neuroleptics: a case control study of flupenthixol. Fritze J; Spreda I Eur Neuropsychopharmacol; 1997 Nov; 7(4):261-6. PubMed ID: 9443657 [TBL] [Abstract][Full Text] [Related]
24. Does long-acting injectable neuroleptic protect against tardive dyskinesia? Goldberg SC; Shenoy RS; Julius D; Hamer RM; Ross B; Minton T; Spiro M Psychopharmacol Bull; 1982 Oct; 18(4):177-9. PubMed ID: 6130561 [No Abstract] [Full Text] [Related]
26. Drug history and tardive dyskinesia. Smith RC; Strizich M; Klass D Am J Psychiatry; 1978 Nov; 135(11):1402-3. PubMed ID: 30289 [No Abstract] [Full Text] [Related]
27. Spontaneous and tardive dyskinesias: clinical and laboratory studies. Casey DE J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):42-7. PubMed ID: 2858480 [TBL] [Abstract][Full Text] [Related]
28. Depot fluphenazine and tardive dyskinesia. Gibson AC Br Med J; 1978 Aug; 2(6134):434. PubMed ID: 687963 [No Abstract] [Full Text] [Related]
29. A depot neuroleptic withdrawal study neurological effects. Wistedt B; Wiles D; Jørgensen A Psychopharmacology (Berl); 1983; 80(2):101-5. PubMed ID: 6136059 [TBL] [Abstract][Full Text] [Related]
30. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Jeste DV; Lacro JP; Palmer B; Rockwell E; Harris MJ; Caligiuri MP Am J Psychiatry; 1999 Feb; 156(2):309-11. PubMed ID: 9989570 [TBL] [Abstract][Full Text] [Related]
32. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Ganzini L; Heintz RT; Hoffman WF; Casey DE Arch Gen Psychiatry; 1991 Mar; 48(3):259-63. PubMed ID: 1671743 [TBL] [Abstract][Full Text] [Related]
33. Factors in the development of severe forms of tardive dyskinesia. Yassa R; Nair NP; Iskander H; Schwartz G Am J Psychiatry; 1990 Sep; 147(9):1156-63. PubMed ID: 1974745 [TBL] [Abstract][Full Text] [Related]
34. The problem of post-psychotic schizophrenic depressions and their pharmacological induction. Long-term studies with fluspirilene and penfluridol and single-blind trial with fluphenazine-decanoate and flupenthixol-decanoate. Floru L; Heinrich K; Wittek F Int Pharmacopsychiatry; 1975; 10(4):230-9. PubMed ID: 814106 [TBL] [Abstract][Full Text] [Related]
36. Diabetes and development of tardive dyskinesia. Woerner MG; Saltz BL; Kane JM; Lieberman JA; Alvir JM Am J Psychiatry; 1993 Jun; 150(6):966-8. PubMed ID: 8098587 [TBL] [Abstract][Full Text] [Related]
40. Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. Waddington JL Int Rev Neurobiol; 1989; 31():297-353. PubMed ID: 2574716 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]